TY - JOUR
T1 - Comparing functional and genomic-based precision medicine in blood cancer patients
AU - Kazianka, Lukas
AU - Pichler, Alexander
AU - Agreiter, Christiane
AU - Rohrbeck, Johannes
AU - Kornauth, Christoph
AU - Porpaczy, Edit
AU - Sillaber, Christian
AU - Sperr, Wolfgang R.
AU - Gleixner, Karoline V.
AU - Hauswirth, Alexander
AU - Jaeger, Ulrich
AU - Valent, Peter
AU - Jonak, Constanze
AU - Porkert, Stefanie
AU - Exner, Ruth
AU - Willenbacher, Wolfgang
AU - Wolf, Dominik
AU - Neumeister, Peter
AU - Prochazka, Katharina
AU - Deutsch, Alexander
AU - Greil, Richard
AU - Schmitt, Clemens
AU - Ristl, Robin
AU - Mayerhoefer, Marius
AU - Simonitsch-Klupp, Ingrid
AU - Pemovska, Tea
AU - Staber, Philipp B.
N1 - Greil: IIIrd Medical Department, Paracelsus Medical University, Salzburg, Austria
PY - 2025/7/14
Y1 - 2025/7/14
N2 - Tumor-agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic-based PM (gPM) and drug screening-based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT-2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy-based, 86% flow cytometry-based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.
AB - Tumor-agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic-based PM (gPM) and drug screening-based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT-2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy-based, 86% flow cytometry-based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.
KW - Strategy
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001473485500001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1002/hem3.70129
DO - 10.1002/hem3.70129
M3 - Original Article
C2 - 40276215
SN - 2572-9241
VL - 9
JO - HEMASPHERE
JF - HEMASPHERE
IS - 4
M1 - e70129
ER -